Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of NK911 and to evaluate its pharmacokinetic profile in man. NK911 was given intravenously to patients with solid tumours every 3 weeks using an infusion pump at a rate of 10 mg DXR equivalent min(-1). The starting dose was 6 mg DXR equivalent m(-2), and the dose was escalated according to the accelerated titration method. A total of 23 patients participated in this study. Neutropenia was the predominant haematological toxicity, and grade 3 or 4 neutropenia was observed at doses of 50 and 67 mg m(-2). Common nonhaematological toxicities were mild alopecia, stomatitis, and anorexia. In the dose identification part of the study, DLTs were observed at a dose of 67 mg m(-2) (grade 4 neutropenia lasting more than 5 days). Thus, this dosage level was determined to be the MTD. Infusion-related reactions were not observed in any cases. The C(5 min) and area under the concentration curve parameters of NK911 exhibited dose-dependent characteristics. Among the 23 patients, a partial response was obtained in one patient with metastatic pancreatic cancer. NK911 was well tolerated and produced only moderate nausea and vomiting at myelosuppressive dosages. The recommended phase II dose was determined to be 50 mg m(-2) every 3 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This same concept was used by Kataoka and colleagues in a series of works leading to development of polymeric micelle NK911, which was evaluated clinically [146, 147].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [146]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationWHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647 · cited 2×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
BackgroundAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Simon, R., Rubinstein, L., Arbuck, S. G., Christian, M. C., Freidlin, B., & Collins, J. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1138 · Cited by 639 · cited 2×
“Dose escalation was performed according to the previously described accelerated titration method (Simon et al, 1997).”
MethodDevelopment of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570 · cited 7×
“The hydrophobic inner core enables NK911 to entrap a sufficient amount of DXR. NK911 has a diameter of about 40 nm (Nakanishi et al, 2001).”
BackgroundMethodSelf-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477 · cited 1×
“No infusionrelated reactions, which are sometimes seen in cases of liposomal drug administration (Uziely et al, 1995; Muggia et al, 1996; Stewart et al, 1998; Gordon et al, 2001), occurred in this trial.”
Background(1991) · PubMed · Cited by 418
Cited by
Items 501–600 of 621
Structured Biodegradable Polymers for Drug Delivery
Mody, N., Agrawal, U., Sharma, R. K., & Vyas, S. P. (2015) · Wiley eBooks · doi:10.1002/9781119041450.ch8 · Cited by 7
Islam, W., Tsutsuki, H., Rahman, A., Harada, A., Zhang, T., Ono, K., Islam, R., Hossen, F., Niidome, T., Sawa, T., et al. (2023) · ACS Applied Polymer Materials · doi:10.1021/acsapm.3c02042 · Cited by 5
Shahriari, M., Liu, S., Ebrahimi, Z., & Cao, L. (2022) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2022.109915 · Cited by 4
Amphiphilic Block Copolymer Based Nanocarriers for Drug and Gene Delivery
Xiong, X.-B., & Lavasanifar, A. (2011) · Fundamental biomedical technologies · doi:10.1007/978-94-007-1248-5_10 · Cited by 5
Perspectives on Clinical Translation of Smart Nanotherapeutics
Lee, J., & Lam, K. S. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.112 · Cited by 4
Du, J., & Lu, H. (2012) · Wiley eBooks · doi:10.1002/0471440264.pst547 · Cited by 5
PEGylated Nanocarriers for Gene Therapy
Mishra, L., Kumari, L., Sharma, Y., Chahar, K., Khare, S., Patel, P., Singh, D., & Kurmi, B. D. (2025) · Springer eBooks · doi:10.1007/978-981-97-7316-9_8 · Cited by 3
Polymeric micelles: “magic bullets” for cancer treatment
Gao, Y., Zhang, M., Chen, Q., Lin, Y., Wu, C., Pan, X., Guo, L., Hiew, T. N., & Huang, Z. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2500054 · Cited by 3
“In addition to PTX, an anti-platinum-resistant ovarian cancer study of DTX PMs (CPC634) polymerized from mPEG -b- p(HPMAm-Lacn) was completed in December 2020 [128], although the results have not yet been published (NCT03742713).”
Chang, L., Wang, W., Huang, P., Lv, Z., Hu, F., Zhang, J., Kong, D., Deng, L., & Dong, A. (2013) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2013.808152 · Cited by 3
Nanotheranostic Approach for the Management of Colorectal Cancer
Sharma, S., Kuppusamy, G., Chowdhury, P. R., & Pamu, D. (2023) · Nanoscience & Nanotechnology-Asia · doi:10.2174/2210681213666230823160616 · Cited by 4
Singh, A. K., Bahadur, S., Yadav, D., & Dabas, H. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230824144727 · Cited by 5
Advances in delivery of nanomedicines and theranostics for targeting breast cancer
Pal, A. K., Nandave, M., & Gautam, R. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85503-7.00014-6 · Cited by 3
Nanomedicine: Size-Related Drug Delivery Applications, Including Periodontics and Endodontics
Ng, X. W., Mundargi, R. C., & Venkatraman, S. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-13575-5_5 · Cited by 4
Preclinical Efficacy and Toxicity Testing of Engineered Nanomaterials
Grossman, J. H., & McNeil, S. E. (2011) · Else Kröner-Fresenius Symposia · doi:10.1159/000328889 · Cited by 4
The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment
Lee, W., Loo, C., Young, P. M., Traini, D., & Rohanizadeh, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-3647-7_2 · Cited by 5
Effects of block copolymer micelles on the pharmacokinetics of encapsulated drugs
Binkhathlan, Z., & Lavasanifar, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816200-2.00017-7 · Cited by 7
PEO-Modified Poly(L -Amino Acid) Micelles for Drug Delivery
Xiong, X.-B., Lavasanifar, A., & Aliabadi, H. M. (2006) · CRC Press eBooks · doi:10.1201/9781420006636.ch18 · Cited by 3
Wei, G., He, W., Bai, Y., & Yu, H. (2022) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2022.109474 · Cited by 3
RetractedInertial migration of cylindrical micelles formed by comb-like copolymer in Poiseuille flow
Lin, M., Shi, Q., Yang, X., & Ding, M. (2024) · Physics of Fluids · doi:10.1063/5.0225531 · Cited by 2
POLYMER MICELLES FOR TUNABLE DRUG RELEASE AND ENHANCED ANTITUMOR EFFICACY
Ponta, A. (2013) · UKnowledge (University of Kentucky) · Cited by 2
Polymer-Based Nanoparticulate Systems as Versatile Agents in the Prognosis and Therapy of Cancer
Tiwari, M. D., & Bellare, J. (2012) · Proceedings of the National Academy of Sciences India Section B Biological Sciences · doi:10.1007/s40011-012-0075-4 · Cited by 2
“[148] who have developed PEG-aspartic acid-doxorubicin nanoparticles (NK911) in the 30–50 nm size range which exhibit a 400-fold higher plasma clearance than Doxil in Phase I trials.”
Background多功能生物可降解聚合物纳米药物载体:设计合成及在肿瘤靶向治疗上的应用
Cheng, R., Meng, F., Zhong, Z., & Chao, D. E. N. G. (2015) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/n972015-00141 · Cited by 2
Gombotz, W. R., & Hoffman, A. S. (2012) · Elsevier eBooks · doi:10.1016/b978-0-08-087780-8.00094-2 · Cited by 3
Polymer Families and Their Extended Activities
Gupta, T. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-66405-7_4 · Cited by 3
Recent Progress of Doxorubicin Nanomedicine in Hematologic Malignancies
Qu, Y., Niu, T., Liu, Z., Chu, B., Zhang, L., & Qian, Z. (2017) · Nanoscience and Nanotechnology Letters · doi:10.1166/nnl.2017.2589 · Cited by 2
Targeted delivery systems for treatment of pancreatic cancer
Karaca, M., & Özsoy, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816200-2.00007-4 · Cited by 4
Zhang, G., Bao, C., & Yi, H. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103287 · Cited by 2
Zhao, G., Chinnathambi, A., Alahmadi, T. A., & Wainwright, M. (2021) · Archives of Medical Science · doi:10.5114/aoms/141173 · Cited by 2
Коbylinska, L. I., Mitina, N., Zaichenko, A., & Стойка, Р. С. (2021) · Springer eBooks · doi:10.1007/978-3-030-76235-3_5 · Cited by 2
Emerging Polymer-Based Nanomaterials for Cancer Therapeutics
Gupta, C. R., Uthale, A., Teni, T. R., Ambre, P., & Coutinho, E. C. (2021) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-74330-7_7 · Cited by 2
Nanomedicine Magic Bullet for Human Cancer
Patnaik, S. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-0549-5.ch014 · Cited by 4
Yanazume, S., Fang, J. Q., Islam, R., Gao, S., & Kobayashi, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050814 · Cited by 2
“; Tokyo, Japan) that encapsulates DOX via the noncovalent bond showed low stability in the blood stream, which releases 50% of the APIs within two hours, resulting in a relatively short plasma half-life (t1/2); consequently, it could not behave as a nanomedicine completely, thus exhibiting an insufficient therapeutic…”
BackgroundPolymeric Nanoparticles as Theranostics for Targeting Solid Tumors
Gautam, L., Thakur, P. S., Goel, I., Sankar, M., Jain, A., Shrivastava, P., Vyas, S., & Vyas, S. P. (2022) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-031-14848-4_10 · Cited by 2
Yang, Y., Sun, H., Awwad, N. S., Ibrahium, H. A., Alhomaid, F. A., El-kott, A. F., & Abdel‐Daim, M. M. (2021) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2021.109125 · Cited by 2
Nanomedicine in Cancer Treatment
Kim, J., & Cho, M. (2014) · Wiley eBooks · doi:10.1002/9781118856017.ch10 · Cited by 2
Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics
Sawdon, A. J., & Peng, C. (2013) · Wiley eBooks · doi:10.1002/9781118636299.ch15 · Cited by 2
Wang, T. (2012) · Digital Repository Service (Northeastern University) · doi:10.17760/d20002706 · Cited by 4
Drug Delivery Vehicles from Stimuli‐Responsive Block Copolymers
Kulkarni, P., & Mallik, S. (2018) · Wiley eBooks · doi:10.1002/9781119156253.ch7 · Cited by 2
Torchilin, V. P. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch29 · Cited by 2
Comparative Characteristics of Dosage Forms of α-Lipoic Acid
Shkolnikova, M. N., Chugunova, O., & Sokolova, O. L. (2020) · E3S Web of Conferences · doi:10.1051/e3sconf/202022206032 · Cited by 2
Zhang, T., Fu, Y., Wang, M., Zhang, X., Geng, C., Lv, Z., Shi, F., & Wang, S. (2026) · European Polymer Journal · doi:10.1016/j.eurpolymj.2026.114635 · Cited by 1
Clinical trials of NK105, a paclitaxel incorporating micellar nanoparticle formation
Kato, K. (2009) · Drug Delivery System · doi:10.2745/dds.24.28 · Cited by 1
Bridging Polymer Science and Medicine Through Supramolecular Nanoassemblies
Cabral, H., & Kataoka, K. (2013) · Advances in polymer science · doi:10.1007/12_2013_271 · Cited by 1
Translational research of DDS based on polymeric micelles
Nishiya, T., Matsumura, Y., & Kataoka, K. (2011) · Folia Pharmacologica Japonica · doi:10.1254/fpj.137.75 · Cited by 1
Self-citationNanomedicine Magic Bullet for Human Cancer
Patnaik, S. (2014) · Advances in chemical and materials engineering book series · doi:10.4018/978-1-4666-6363-3.ch009 · Cited by 1
Tumor-specific Liposomal Nanomedicines
ElBayoumi, T. A., & Torchilin, V. P. (2011) · Science Publishers eBooks · doi:10.1201/b11076-18 · Cited by 1
Brown, A. M., Miranda-Alarćon, Y. S., Knoll, G. A., Santora, A. M., & Banerjee, I. A. (2016) · International Journal of Nanoscience · doi:10.1142/s0219581x1650023x · Cited by 1
A Facile Synthesis of Acid-Activatable Nanoparticles for Efficient Intracellular Doxorubicin Release
Ming, C., Song, X. W., Zhang, Y. J., Xu, C., Chen, P., Xia, R., Hu, T. L., Qian, J. S., & Wu, K. L. (2017) · Journal of nano research · doi:10.4028/www.scientific.net/jnanor.46.20 · Cited by 1
Rational Design of Polymeric Micelle for Cancer Therapy
Huang, Y., Sun, J., & Li, S. (2016) · Advances in medical technologies and clinical practice book series · doi:10.4018/978-1-5225-0751-2.ch012 · Cited by 1
(2005) · Drug Delivery · doi:10.1080/10717540590959206 · Cited by 1
Stimuli-responsive protein fibers for advanced applications
Jain, A., Alex, T. S., Lang, D. K., & Gupta, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91248-8.00013-1 · Cited by 1
Stem Cells Therapy for Cartilage Regeneration in Clinic: Challenges and Opportunities
Shahnazari, M., Malih, S., Naeimi, R., Savari, M., Shokrollah, N., Samadi, P., & Sheykhhasan, M. (2023) · Springer eBooks · doi:10.1007/978-981-99-2452-3_17 · Cited by 2
Investigating the Anticancer Effects of Nanoparticles in Cancer Treatment
Noor, H., Coțe, A., Micu, A., Bontea, M. G., & Pirvut, V. (2023) · Clinical Cancer Investigation Journal · doi:10.51847/ohlsslcifw · Cited by 1
“[22] Because chemotherapeutic agents are usually insoluble in water and their therapeutic results are compromised using systemic toxicity and short circulation time, significant studies have been done during the last century to improve the therapeutic benefits and reduce these limitations of…”
BackgroundBhadouria, N., Alam, A., & Kaur, A. (2024) · Pharmaceutical Nanotechnology · doi:10.2174/0122117385282163240220072251 · Cited by 1
Injectable Multistage Nanovectors for Enhancing Imaging Contrast and Directed Therapy
Godin, B., Serda, R. E., Liu, X., & Ferrari, M. (2012) · Nanostructure science and technology · doi:10.1007/978-1-4614-2305-8_10 · Cited by 1
Polymeric Nanosystems for Integrated Image-Guided Cancer Therapy
Singh, A., Iyer, A. K., & Amiji, M. M. (2014) · Frontiers in nanobiomedical research · doi:10.1142/9789814520652_0006 · Cited by 1
Parrott, M. C., & Dunn, S. S. (2018) · Polymers and polymeric composites · doi:10.1007/978-3-319-92066-5_10-1 · Cited by 1
Singh, K. V. (2020) · AIP conference proceedings · doi:10.1063/5.0000843 · Cited by 1
Emerging Protein and Peptide-Based Nanomaterials for Cancer Therapeutics
Choudhury, S., Aggarwal, N., Panda, J. J., & Mishra, J. (2021) · Nanotechnology in the life sciences · doi:10.1007/978-3-030-74330-7_6 · Cited by 1
Parrott, M. C., & Dunn, S. S. (2019) · Polymers and polymeric composites · doi:10.1007/978-3-319-95990-0_10 · Cited by 2
Theranostic Approaches for Diagnosis and Treatment of Cancer: An Update
Ali, R., Ahmed, F., & Chauhan, M. K. (2023) · Biological and medical physics, biomedical engineering · doi:10.1007/978-981-19-9786-0_18 · Cited by 1
Micellar Structures as Drug Delivery Systems
Nishiyama, N., Cabral, H., & Kataoka, K. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch32 · Cited by 1
Targeted delivery of anti-cancer drugs by MS2 virus-like particles
Yan, R. (2015) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Polysaccharide-based Polyion Complex Micelles as New Delivery Systems for Hydrophilic Cationic Drugs
Soliman, G. M. (2009) · doi:10.71781/4636 · Cited by 3
Microfluidics Applications in Cancer Drug Delivery
Zhang, H., & Shen, Y. (2016) · Wiley eBooks · doi:10.1002/9783527694396.ch5 · Cited by 1
Bioengineering targeted nanodrugs for hematologic malignancies: an innovation in pediatric oncology
Krishnan, V. (2015) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/41zm-9f54 · Cited by 1
Drug Delivery: Tumor-Targeted Systems
Li, Y., & Lee, C.-P. (2015) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120050256 · Cited by 1
Π-π Stacked Polymeric Micelles as Carriers of Anticancer Therapeutics for Hematological Malignancies
Varela-Moreira, A. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/145 · Cited by 2
Combined Cancer Therapy by Micellar-Encapsulated Drugs and Ultrasound
Rapoport, N. Y. (2006) · CRC Press eBooks · doi:10.1201/9781420006636.ch21 · Cited by 3
TARGETED THERAPY FOR LIVER FIBROSIS AND CANCER
Zhang, Y. (2014) · D-Scholarship@Pitt (University of Pittsburgh)
López, M. V. L. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Overview on Nanocarriers as Delivery Systems
Shen, H., Blanco, E., Godin, B., Serda, R. E., Streiff, A. K., & Ferrari, M. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch27 · Cited by 1
Synthesis and Solution Properties of Water-soluble Fullerene Polymeric Systems
Yao, Z. (2011) · UWSpace (University of Waterloo)
Soleimani, R. (2013) · Scholarship@Western (Western University)
"Nanotheranostics" for Tumor Imaging and Targeted Drug Delivery.
Zou, P. (2011) · Deep Blue (University of Michigan)
PH SENSITIVE RNA AND DRUG DELIVERY SYSTEMS
Sutton, D. M. (2007) · OhioLink ETD Center (Ohio Library and Information Network)
Nanotechnology toward Advancing Personalized Medicine
Sakamoto, J. H., Godin, B., Hu, Y., Blanco, E., van de Ven, A. L., Vellaichamy, A., Murphy, M. B., Francesca, S. L., Schuenemeyer, T., Given, B. D., et al. (2014) · Pan Stanford Publishing eBooks · doi:10.1201/b15465-2
Anticancer agent-incorporating immunomicelles
Yamamoto, Y., Hamaguchi, T., & Matsumura, Y. (2015) · Drug Delivery System · doi:10.2745/dds.30.10
Self-citationCore-Shell Nanoparticles for Biomedical Applications
Elsabahy, M., & Wooley, K. L. (2014) · Frontiers in nanobiomedical research · doi:10.1142/9789814520652_0013
Herceg, V., Lange, N., & Allémann, É. (2016) · Springer eBooks · doi:10.1007/978-3-319-41421-8_17
Nano-particles Containing Anticancer Drug
Chakraborty, D., & Yolmo, N. L. (2017) · Pharmatutor
Song, L. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Mikhail, A. S. (2013) · TSpace (University of Toronto)
Hoang, B. (2014) · TSpace (University of Toronto)
Advances in tumor-targeted therapy using nanomedicine.
Karukonda, D. (2017) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2800
Roles of Passively and Actively Targeted Block Copolymer Micelles in Cancer Therapy
Lee, H. H. N. (2011) · TSpace (University of Toronto)
Goldswain, T. L. (2017) · SUNScholar (Stellenbosch University)
Anticancer Agents: Polymeric Nanomedicines
Tong, R., & Cheng, J. (2017) · CRC Press eBooks · doi:10.1081/e-ebppc-120052058
NONCOVALENT FLUOROUS INTERACTIONS: NEW APPROACHES FOR DRUG DISCOVERY AND DRUG DELIVERY
GALLI, C. (2018) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/c-galli_phd2018-01-19
Development of multi-functionalized polymeric carriers for delivery of anticancer drug combinations
Phuoc, D. H. H. (2013) · National University of Singapore
Liu, J., Tan, H., & Zeng, Q. (2021) · Archives of Medical Science · doi:10.5114/aoms/143792
大庭, 誠., & Kataoka, K. (2009) · Farumashia · doi:10.14894/faruawpsj.45.3_227
Anticancer Agents: Polymeric Nanomedicines
Tong, R., & Cheng, J. (2015) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120052058
Implementation of Nanoparticles in Cancer Therapy
Bayır, E., Bilgi, E., & Şendemir, A. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-1762-7.ch047
Nanoparticles for Cancer Therapy
Rekha, K., Dutta, N., Thiruvengadam, M., Shariati, M. A., Khan, M. U., Usman, M., Bhatta, M., Ghosh, K., Arif, S., & Naeem, M. S. (2022) · Wiley eBooks · doi:10.1002/9781119857747.ch15
Synthesis and Biological Use of Nanomaterials
Hatipoglu, M. K., & Süt, P. A. (2022) · Topics in applied physics · doi:10.1007/978-3-030-93460-6_29
Nanotheranostic Approach for Cancer Treatment
Ahmad, M. Z., Pathak, K., Bhatnagar, D., Ladhe, S., Kumar, D., Saikia, R., & Das, A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_296-1
Targeted breast cancer treatment: progress and challenges
Kilor, V. A., Dhote, V. V., Sapkal, N. P., & Khan, S. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91763-6.00014-x
Advantages of Nanomedicine Over Conventional Therapeutics
Butt, A. M., Abdullah, N., Sattar, A., Hussain, T., Pandey, M., Kumar, T., Garg, U., Rathee, J., Jain, N., & Abeer, M. M. (2023) · Learning materials in biosciences · doi:10.1007/978-981-99-7626-3_2
Metadata
- Authors
- Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., & Watanabe, N.
- Affiliations
- National Cancer Center Hospital East (JP)
- National Cancer Center Hospital (JP)
- Nippon Kayaku (Japan) (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2004-10-12
- Volume
- 91
- Issue
- 10
- Pages
- 1775-1781
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2410050
- OpenAlex
- W2056347214
- Cited by
- 623
- References
- 17
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 20 · 2023: 18 · 2022: 28 · 2021: 35 · 2020: 28 · 2019: 23 · 2018: 25 · 2017: 37 · 2016: 42 · 2015: 38 · 2014: 53 · 2013: 28 · 2012: 54
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- doxorubicin, polymeric micelles, supramolecular nanocarriers, maximum tolerated dose, dose-limiting toxicity, neutropenia, pharmacokinetics, solid tumors, metastatic pancreatic cancer, accelerated titration, recommended phase 2 dose, drug delivery
- MeSH terms
- Aged, Antineoplastic Agents, Doxorubicin, Drug Administration Schedule, Female, Humans, Male, Micelles, Middle Aged, Nausea, Neoplasms, Neutropenia, Peptides, Polyethylene Glycols, Vomiting, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.